董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Maria Maccecchini | 女 | Director | 74 | 6.72万美元 | 未持股 | 2025-09-19 |
| Panna Sharma | 男 | Chief Executive Officer, President and Director | 54 | 109.06万美元 | 未持股 | 2025-09-19 |
| Donald Jeff Keyser | 男 | Chairman of the Board | 72 | 7.22万美元 | 未持股 | 2025-09-19 |
| David S. Silberstein | 男 | Director | 74 | 7.82万美元 | 未持股 | 2025-09-19 |
| Vijay Chandru | 男 | Director | 71 | 8.32万美元 | 未持股 | 2025-09-19 |
| Lee T. Schalop | 男 | Director | 61 | 未披露 | 未持股 | 2025-09-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Panna Sharma | 男 | Chief Executive Officer, President and Director | 54 | 109.06万美元 | 未持股 | 2025-09-19 |
| David R. Margrave | 男 | Chief Financial Officer and Secretary | 65 | 75.29万美元 | 未持股 | 2025-09-19 |
| Kishor G. Bhatia | 男 | Chief Scientific Officer | 70 | 53.91万美元 | 未持股 | 2025-09-19 |
董事简历
中英对照 | 中文 | 英文- Maria Maccecchini
-
Maria Maccecchini创立了Annovis，前身为QR Pharma，自2008年5月起担任总裁兼首席执行官。她曾担任Robin Hood Ventures公司（从2002年到2009年）、MidAtlantic Angel Group（从2005年到2009年）的两个天使集团的合伙人兼董事。她于1992年创立Symphony Pharmaceuticals/Annovis公司（生物技术公司，于2001年出售给Transgenomic公司），并担任首席执行官。在此之前，从1987年到1991年，她是Bachem Bioscience（瑞士Bachem AG的美国子公司，Mallinckrodt的分子生物学主管）的总经理。MacCecchini博士在加州理工学院（Caltech）和罗氏免疫学研究所（Roche Institute of Immunology）进行博士后研究。她获得了生物化学博士学位，来自巴塞尔生物中心，并在洛克菲勒大学获得了为期两年的访问奖学金。MacCecchini博士在生物技术公司、促进企业家精神的组织、国际贸易、妇女和慈善组织的几个董事会任职。她自2016年以来一直担任Wharton Business School的讲师。
Maria Maccecchini,founded Annovis and has served as President and CEO and as a director since May 2008. She has over 30 years of experience in neuroscience and the workings of the brain. She was partner and director of two angel groups, Robin Hood Ventures, from 2002 to 2009, and MidAtlantic Angel Group, from 2005 to 2009. In 1992, she founded and became chief executive officer of Symphony Pharmaceuticals/Annovis, a biotech company, which was sold in 2001 to Transgenomic. Prior to that, from 1987 to 1991 she was General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini conducted post-doctoral research at Caltech and the Roche Institute of Immunology. She earned a Ph.D. in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University. Dr. Maccecchini serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade, women and charitable organizations. She has been a lecturer at Wharton School of Business since 2016. - Maria Maccecchini创立了Annovis，前身为QR Pharma，自2008年5月起担任总裁兼首席执行官。她曾担任Robin Hood Ventures公司（从2002年到2009年）、MidAtlantic Angel Group（从2005年到2009年）的两个天使集团的合伙人兼董事。她于1992年创立Symphony Pharmaceuticals/Annovis公司（生物技术公司，于2001年出售给Transgenomic公司），并担任首席执行官。在此之前，从1987年到1991年，她是Bachem Bioscience（瑞士Bachem AG的美国子公司，Mallinckrodt的分子生物学主管）的总经理。MacCecchini博士在加州理工学院（Caltech）和罗氏免疫学研究所（Roche Institute of Immunology）进行博士后研究。她获得了生物化学博士学位，来自巴塞尔生物中心，并在洛克菲勒大学获得了为期两年的访问奖学金。MacCecchini博士在生物技术公司、促进企业家精神的组织、国际贸易、妇女和慈善组织的几个董事会任职。她自2016年以来一直担任Wharton Business School的讲师。
- Maria Maccecchini,founded Annovis and has served as President and CEO and as a director since May 2008. She has over 30 years of experience in neuroscience and the workings of the brain. She was partner and director of two angel groups, Robin Hood Ventures, from 2002 to 2009, and MidAtlantic Angel Group, from 2005 to 2009. In 1992, she founded and became chief executive officer of Symphony Pharmaceuticals/Annovis, a biotech company, which was sold in 2001 to Transgenomic. Prior to that, from 1987 to 1991 she was General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini conducted post-doctoral research at Caltech and the Roche Institute of Immunology. She earned a Ph.D. in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University. Dr. Maccecchini serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade, women and charitable organizations. She has been a lecturer at Wharton School of Business since 2016.
- Panna Sharma
-
Panna Sharma自2018年7月起担任我们的首席执行官兼总裁，自2018年8月起担任董事。作为首席执行官，Sharma先生监督我们使用AI和基因组学来开发我们的治疗产品线，以创新肿瘤学中精密疗法的拯救，振兴和发展。从2010年5月至2018年2月，Sharma先生担任纳斯达克公司Cancer Genetics的总裁，首席执行官兼董事，该公司为全球医疗机构提供基于DNA的癌症诊断和服务。Sharma先生于2001年创立了TSG Partners，这是一家专业咨询集团，将企业战略和企业融资结合在一起，为生命科学、生物技术和环境科学领域的公司和投资者创造股东价值。在加入TSG之前，Sharma先生曾担任IXL Inc.的电子商务解决方案高级副总裁和首席战略官，该公司后来与Scient合并。在加入IXL Inc.之前的六年里，Sharma先生帮助成功地创立，管理和出售或上市了另外两家咨询和专业服务公司。Sharma从1996年到1998年担任Interactive Solutions，Inc.合伙人。在此之前，Sharma先生曾担任Putnam Investment Management，LLC和美国银行公司的顾问。Sharma先生持有波士顿大学（Boston University）科学哲学、神经网络与人工智能理学学士学位。
Panna Sharma,oversees Lantern Pharma Inc. Lantern Pharma Inc. e of AI and genomics in developing Lantern Pharma Inc. therapy product pipeline to innovate the rescue, revitalization and development of precision therapeutics in oncology. From May 2010 to February 2018, Mr. Sharma served as President, Chief Executive Officer and director of Cancer Genetics, a Nasdaq company and provider of DNA-based cancer diagnostics and services to medical institutions throughout the world. In 2001, Mr. Sharma founded TSG Partners, a specialty advisory group combining corporate strategy and corporate finance to create stockholder value for companies and investors in the life sciences, biotechnology and environmental sciences sectors. Prior to TSG, Mr. Sharma served in the roles of Senior Vice President of E-Business Solutions and Chief Strategy Officer at iXL Inc. (later merged with Scient). For the six years prior to his being at iXL Inc., Mr. Sharma helped successfully found, manage and sell or take public two other consulting and professional services firms. From 1996 to 1998, Mr. Sharma was a partner at Interactive Solutions, Inc. Prior to that, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma currently serves as a Board member of Continental Lithium, Inc. Mr. Sharma holds a Bachelor of Science in the Philosophy of Science, Neural Networks and Artificial Intelligence from Boston University. - Panna Sharma自2018年7月起担任我们的首席执行官兼总裁，自2018年8月起担任董事。作为首席执行官，Sharma先生监督我们使用AI和基因组学来开发我们的治疗产品线，以创新肿瘤学中精密疗法的拯救，振兴和发展。从2010年5月至2018年2月，Sharma先生担任纳斯达克公司Cancer Genetics的总裁，首席执行官兼董事，该公司为全球医疗机构提供基于DNA的癌症诊断和服务。Sharma先生于2001年创立了TSG Partners，这是一家专业咨询集团，将企业战略和企业融资结合在一起，为生命科学、生物技术和环境科学领域的公司和投资者创造股东价值。在加入TSG之前，Sharma先生曾担任IXL Inc.的电子商务解决方案高级副总裁和首席战略官，该公司后来与Scient合并。在加入IXL Inc.之前的六年里，Sharma先生帮助成功地创立，管理和出售或上市了另外两家咨询和专业服务公司。Sharma从1996年到1998年担任Interactive Solutions，Inc.合伙人。在此之前，Sharma先生曾担任Putnam Investment Management，LLC和美国银行公司的顾问。Sharma先生持有波士顿大学（Boston University）科学哲学、神经网络与人工智能理学学士学位。
- Panna Sharma,oversees Lantern Pharma Inc. Lantern Pharma Inc. e of AI and genomics in developing Lantern Pharma Inc. therapy product pipeline to innovate the rescue, revitalization and development of precision therapeutics in oncology. From May 2010 to February 2018, Mr. Sharma served as President, Chief Executive Officer and director of Cancer Genetics, a Nasdaq company and provider of DNA-based cancer diagnostics and services to medical institutions throughout the world. In 2001, Mr. Sharma founded TSG Partners, a specialty advisory group combining corporate strategy and corporate finance to create stockholder value for companies and investors in the life sciences, biotechnology and environmental sciences sectors. Prior to TSG, Mr. Sharma served in the roles of Senior Vice President of E-Business Solutions and Chief Strategy Officer at iXL Inc. (later merged with Scient). For the six years prior to his being at iXL Inc., Mr. Sharma helped successfully found, manage and sell or take public two other consulting and professional services firms. From 1996 to 1998, Mr. Sharma was a partner at Interactive Solutions, Inc. Prior to that, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma currently serves as a Board member of Continental Lithium, Inc. Mr. Sharma holds a Bachelor of Science in the Philosophy of Science, Neural Networks and Artificial Intelligence from Boston University.
- Donald Jeff Keyser
-
Donald Jeff Keyser自2018年1月起担任董事，自2019年11月起担任董事长。Keyser博士创立了Renibus Therapeutics（一家为诊断，治疗和预防肾脏疾病开发新型疗法的公司），并自2017年起担任其董事，总裁兼首席运营官。Keyser博士还创立了ZS Pharma，并自2008年以来担任该公司的董事兼首席运营官，直到2015年12月该公司被Astra Zeneca以27亿美元收购。Keyser博士是Adams Respiratory Therapeutics的Mucinex产品线的发明者。Keyser博士在1998年至2004年期间为Adams Respiratory Therapeutics开发和执行研发和监管战略，担任开发和监管事务的Vice President。Adams Resiratory Therapeutics被Reckitt Benckiser以23亿美元收购。他此前曾担任Encysive Pharmaceuticals公司的首席合规官兼Vice President监管事务、Medeva Americas公司的Vice President技术和监管事务。Marion Merrell Dow监管事务主管和雅培公司监管负责人。Keyser博士在克里顿大学（Creighton University）获得药学学位，在克里顿大学（Creighton University）获得法学博士学位，在密苏里-堪萨斯城大学（University of Missouri-Kansas City）获得MPA学位，在德克萨斯大学达拉斯分校（University of Texas at Dallas）获得经济学博士学位。
Donald Jeff Keyser,has served as a director since January 2018 and Chairman since November 2019. Since 2017, Dr. Keyser has served in leadership positions with Renibus Therapeutics, a company developing novel therapies for the diagnosis, treatment and prevention of kidney disease. Dr. Keyser founded Renibus and currently serves as director, president and chief executive officer. Dr. Keyser also served as chief operating officer of Renibus from 2017 until becoming chief executive officer in March 2024. Dr. Keyser also founded ZS Pharma and served since 2008 as a director and chief operating officer of that company until December 2015 when it was acquired by Astra Zeneca for $2.7 Billion. Dr. Keyser was the inventor of the Mucinex product line for Adams Respiratory Therapeutics. Dr. Keyser developed and executed the R&D and Regulatory strategy for Adams Respiratory Therapeutics as Vice President of Development and Regulatory Affairs during his period there from 1998 to 2004. Adams Respiratory Therapeutics was acquired by Reckitt Benckiser for $2.3 Billion. He was previously employed as Chief Compliance Officer & Vice President Regulatory Affairs, Encysive Pharmaceuticals, Vice President Technical & Regulatory Affairs, Medeva Americas, Sr. Director Regulatory Affairs, Marion Merrell Dow and Regulatory Principal, Abbott Laboratories. Dr. Keyser received his Pharmacy degree from Creighton University, a Juris Doctorate from Creighton University, a MPA from the University of Missouri-Kansas City and a PhD in Economics from The University of Texas at Dallas. - Donald Jeff Keyser自2018年1月起担任董事，自2019年11月起担任董事长。Keyser博士创立了Renibus Therapeutics（一家为诊断，治疗和预防肾脏疾病开发新型疗法的公司），并自2017年起担任其董事，总裁兼首席运营官。Keyser博士还创立了ZS Pharma，并自2008年以来担任该公司的董事兼首席运营官，直到2015年12月该公司被Astra Zeneca以27亿美元收购。Keyser博士是Adams Respiratory Therapeutics的Mucinex产品线的发明者。Keyser博士在1998年至2004年期间为Adams Respiratory Therapeutics开发和执行研发和监管战略，担任开发和监管事务的Vice President。Adams Resiratory Therapeutics被Reckitt Benckiser以23亿美元收购。他此前曾担任Encysive Pharmaceuticals公司的首席合规官兼Vice President监管事务、Medeva Americas公司的Vice President技术和监管事务。Marion Merrell Dow监管事务主管和雅培公司监管负责人。Keyser博士在克里顿大学（Creighton University）获得药学学位，在克里顿大学（Creighton University）获得法学博士学位，在密苏里-堪萨斯城大学（University of Missouri-Kansas City）获得MPA学位，在德克萨斯大学达拉斯分校（University of Texas at Dallas）获得经济学博士学位。
- Donald Jeff Keyser,has served as a director since January 2018 and Chairman since November 2019. Since 2017, Dr. Keyser has served in leadership positions with Renibus Therapeutics, a company developing novel therapies for the diagnosis, treatment and prevention of kidney disease. Dr. Keyser founded Renibus and currently serves as director, president and chief executive officer. Dr. Keyser also served as chief operating officer of Renibus from 2017 until becoming chief executive officer in March 2024. Dr. Keyser also founded ZS Pharma and served since 2008 as a director and chief operating officer of that company until December 2015 when it was acquired by Astra Zeneca for $2.7 Billion. Dr. Keyser was the inventor of the Mucinex product line for Adams Respiratory Therapeutics. Dr. Keyser developed and executed the R&D and Regulatory strategy for Adams Respiratory Therapeutics as Vice President of Development and Regulatory Affairs during his period there from 1998 to 2004. Adams Respiratory Therapeutics was acquired by Reckitt Benckiser for $2.3 Billion. He was previously employed as Chief Compliance Officer & Vice President Regulatory Affairs, Encysive Pharmaceuticals, Vice President Technical & Regulatory Affairs, Medeva Americas, Sr. Director Regulatory Affairs, Marion Merrell Dow and Regulatory Principal, Abbott Laboratories. Dr. Keyser received his Pharmacy degree from Creighton University, a Juris Doctorate from Creighton University, a MPA from the University of Missouri-Kansas City and a PhD in Economics from The University of Texas at Dallas.
- David S. Silberstein
-
DavidS.Silberstein自2018年6月起担任董事。Silberstein博士从2013年开始担任Biomimetix Pharmaceutical，Inc.的首席运营官。Silberstein博士自2016年以来一直担任BMI的董事。Silberstein博士在哥伦比亚大学（Columbia University）获得免疫学博士学位，在哈佛医学院（Harvard Medical School）/布莱根妇女医院（Brigham&Women&8217；s Hospital）获得博士后培训。Silberstein博士继续在哈佛大学（Harvard）工作了七年，领导一个研究炎症生物化学的研究团队。随后，Silberstein博士在阿斯利康制药公司（AstraZeneca Pharmaceuticals）工作了20年，在那里他在基因组学，转化科学，全公司范围的投资组合管理以及两种产品的科学支持方面发挥了领导作用，总销售额超过300亿美元。自2013年以来，Silberstein博士曾与多家早期生物技术公司独立合作，并担任投资公司的顾问。目前的工作包括担任NCI资助的多发性脑转移患者临床试验的Pri新华保险pal研究员。
David S. Silberstein,has served as a director since June 2018. Dr. Silberstein has served as chief operating officer/VP R&D of BioMimetix JV, LLC since 2013. Dr. Silberstein has served as a director of Biological Mimetics, Inc. since 2016. Dr. Silberstein received his PhD in Immunology at Columbia University and Postdoctoral training at Harvard Medical School/Brigham & Women's Hospital. Dr. Silberstein continued for seven years as Assistant Professor at Harvard, leading a research team studying the biochemistry of inflammation. This was followed by 20 years at AstraZeneca Pharmaceuticals where Dr. Silberstein had leadership roles in genomics, translational science, company-wide portfolio management, and science support for two products through launch to aggregate sales of greater than $30 billion. Since 2013, Dr. Silberstein has worked independently with a number of early stage biotech companies and as a consultant to investment firms. Over this period he has served in leadership roles for NCI oncology trials, including Principal Investigator of a trial in patients with multiple brain metastases. - DavidS.Silberstein自2018年6月起担任董事。Silberstein博士从2013年开始担任Biomimetix Pharmaceutical，Inc.的首席运营官。Silberstein博士自2016年以来一直担任BMI的董事。Silberstein博士在哥伦比亚大学（Columbia University）获得免疫学博士学位，在哈佛医学院（Harvard Medical School）/布莱根妇女医院（Brigham&Women&8217；s Hospital）获得博士后培训。Silberstein博士继续在哈佛大学（Harvard）工作了七年，领导一个研究炎症生物化学的研究团队。随后，Silberstein博士在阿斯利康制药公司（AstraZeneca Pharmaceuticals）工作了20年，在那里他在基因组学，转化科学，全公司范围的投资组合管理以及两种产品的科学支持方面发挥了领导作用，总销售额超过300亿美元。自2013年以来，Silberstein博士曾与多家早期生物技术公司独立合作，并担任投资公司的顾问。目前的工作包括担任NCI资助的多发性脑转移患者临床试验的Pri新华保险pal研究员。
- David S. Silberstein,has served as a director since June 2018. Dr. Silberstein has served as chief operating officer/VP R&D of BioMimetix JV, LLC since 2013. Dr. Silberstein has served as a director of Biological Mimetics, Inc. since 2016. Dr. Silberstein received his PhD in Immunology at Columbia University and Postdoctoral training at Harvard Medical School/Brigham & Women's Hospital. Dr. Silberstein continued for seven years as Assistant Professor at Harvard, leading a research team studying the biochemistry of inflammation. This was followed by 20 years at AstraZeneca Pharmaceuticals where Dr. Silberstein had leadership roles in genomics, translational science, company-wide portfolio management, and science support for two products through launch to aggregate sales of greater than $30 billion. Since 2013, Dr. Silberstein has worked independently with a number of early stage biotech companies and as a consultant to investment firms. Over this period he has served in leadership roles for NCI oncology trials, including Principal Investigator of a trial in patients with multiple brain metastases.
- Vijay Chandru
-
Vijay Chandru自2019年10月起担任董事。目前，Chandru博士是Opford Foundation的联合创始人，该基金会是印度的非营利组织，拥有孤儿疾病开放平台，其使命是支持开发负担得起和可获得的孤儿疾病治疗药物，其中许多是罕见的遗传疾病。他也是印度Strand Life Sciences领先的精密医学解决方案公司的联合创始人，该公司是印度科学研究所的分支机构，目前拥有20多个诊断实验室和遍布印度的800多名员工。他于2000年至2018年担任Strand Life Sciences执行主席。他是世界经济论坛的技术先驱（2006年以来），也曾当选the Association of Biotech LED Enterprises（ABLE）（代表印度生物技术行业的顶级贸易机构）的总裁（2009年至2012年）。Chandru博士是一位学术企业家，其学术生涯跨越了近四十年。在麻省理工学院获得博士学位后，他于1980年代在普渡大学（Purdue University）担任了十年的终身教授，此后在班加罗尔的印度科学研究所（Indian Institute of Science）担任终身教授。他是科学与工程学院的院士，目前是印度国家工程院生物工程方面的杰出技术专家。
Vijay Chandru,has served as a director since October 2019. Currently, Dr. Chandru is a co-founder of OPFORD Foundation, a non-profit in India with an open platform for orphan diseases and with a mission to support development of affordable and accessible therapeutics for orphan diseases of which many are rare genetic disorders. He was also a co-founder of Strand Life Sciences, India's leading precision medicine solutions company, an offshoot of the Indian Institute of Science, which now has over 20 diagnostic laboratories and over 800 employees spread across India. He served as Executive Chairman of Strand Life Sciences from 2000 to 2018, and currently serves as a Director and Chair of the Science Advisory Board at Strand Life Sciences. A technology pioneer of the World Economic Forum since 2006, he was elected President (2009-2012) of the Association of Biotech Led Enterprises (ABLE), the apex trade body that represents the Indian biotech industry. Dr. Chandru co-founded two startups in the last five years – Yantri Labs Inc. (an algorithmic trading technology company), and CrisprBits Private Limited, a CRISPR technology mediated company in diagnostics and gene-editing. Dr. Chandru serves as a Director of Yantri Labs and as the acting Chief Scientific Officer of CrisprBits. Dr. Chandru is an academic entrepreneur whose academic career has spanned almost four decades. After his doctoral work at MIT he was a tenured professor at Purdue University for a decade in the 1980s and at the Indian Institute of Science in Bangalore since then. A fellow of both the academy of science and engineering in India, he was elected to fellowship of the American Association for the Advancement of Science in 2024. - Vijay Chandru自2019年10月起担任董事。目前，Chandru博士是Opford Foundation的联合创始人，该基金会是印度的非营利组织，拥有孤儿疾病开放平台，其使命是支持开发负担得起和可获得的孤儿疾病治疗药物，其中许多是罕见的遗传疾病。他也是印度Strand Life Sciences领先的精密医学解决方案公司的联合创始人，该公司是印度科学研究所的分支机构，目前拥有20多个诊断实验室和遍布印度的800多名员工。他于2000年至2018年担任Strand Life Sciences执行主席。他是世界经济论坛的技术先驱（2006年以来），也曾当选the Association of Biotech LED Enterprises（ABLE）（代表印度生物技术行业的顶级贸易机构）的总裁（2009年至2012年）。Chandru博士是一位学术企业家，其学术生涯跨越了近四十年。在麻省理工学院获得博士学位后，他于1980年代在普渡大学（Purdue University）担任了十年的终身教授，此后在班加罗尔的印度科学研究所（Indian Institute of Science）担任终身教授。他是科学与工程学院的院士，目前是印度国家工程院生物工程方面的杰出技术专家。
- Vijay Chandru,has served as a director since October 2019. Currently, Dr. Chandru is a co-founder of OPFORD Foundation, a non-profit in India with an open platform for orphan diseases and with a mission to support development of affordable and accessible therapeutics for orphan diseases of which many are rare genetic disorders. He was also a co-founder of Strand Life Sciences, India's leading precision medicine solutions company, an offshoot of the Indian Institute of Science, which now has over 20 diagnostic laboratories and over 800 employees spread across India. He served as Executive Chairman of Strand Life Sciences from 2000 to 2018, and currently serves as a Director and Chair of the Science Advisory Board at Strand Life Sciences. A technology pioneer of the World Economic Forum since 2006, he was elected President (2009-2012) of the Association of Biotech Led Enterprises (ABLE), the apex trade body that represents the Indian biotech industry. Dr. Chandru co-founded two startups in the last five years – Yantri Labs Inc. (an algorithmic trading technology company), and CrisprBits Private Limited, a CRISPR technology mediated company in diagnostics and gene-editing. Dr. Chandru serves as a Director of Yantri Labs and as the acting Chief Scientific Officer of CrisprBits. Dr. Chandru is an academic entrepreneur whose academic career has spanned almost four decades. After his doctoral work at MIT he was a tenured professor at Purdue University for a decade in the 1980s and at the Indian Institute of Science in Bangalore since then. A fellow of both the academy of science and engineering in India, he was elected to fellowship of the American Association for the Advancement of Science in 2024.
- Lee T. Schalop
-
Lee T. Schalop是Oncoceutics，Inc.的联合创始人，该公司是一家临床阶段药物发现和开发公司，2009年至2021年在Oncoceutics担任过多个行政职务，包括2009年至2016年的首席商务官、2016年至2020年的首席运营官以及2020年至2021年1月的首席执行官，当时Oncoceutuics以4.5亿美元的价格出售给了Chimerix Inc.（NASD：CMRX）。在共同创立Oncoceutics之前，沙洛普博士曾就读于阿尔伯特·爱因斯坦医学院，于2008年获得医学博士学位。在上医学院之前，沙洛普博士曾在几家华尔街大公司的金融行业工作了超过19年，包括摩根士丹利、J.P. Morgan、瑞士信贷和美银证券，其中包括1985年至1993年担任投资银行家，以及1993年至2004年担任研究分析师。Schalop博士在TME Pharma N.V.（Euronext Growth Paris：ALTME）的监事会任职，并曾担任Chimerix公司的董事会观察员，直到该公司于2025年4月出售给爵士制药。他还是宾夕法尼亚大学生命科学与管理Vagelos项目顾问委员会成员。他以优异成绩毕业于宾夕法尼亚大学，在那里他获得了该大学沃顿商学院和文理学院的双学位。
Lee T. Schalop,has served as a director since July 2025. In 2009, Dr. Schalop was a co-founder of Oncoceutics, Inc., a clinical-stage drug discovery and development company, and served in various executive roles at Oncoceutics from 2009 to 2021, including Chief Business Officer from 2009 to 2016, Chief Operating Officer from 2016 to 2020 and Chief Executive Officer from 2020 to January 2021, at which time Oncoceutuics was sold to Chimerix Inc. (NASD: CMRX) for $450 million. Prior to co-founding Oncoceutics, Dr. Schalop attended the Albert Einstein College of Medicine, graduating with a doctor of medicine degree in 2008. Before attending medical school, Dr. Schalop spent more than 19 years in the financial industry at several major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of America Securities, including serving as an investment banker from 1985 to 1993 and a research analyst from 1993 to 2004. Dr. Schalop serves on the Supervisory Board of TME Pharma N.V. (Euronext Growth Paris: ALTME), and he served as a Board Observer at Chimerix Inc. until its sale to Jazz Pharmaceuticals in April 2025. He also sits on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania. He is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University's Wharton School and College of Arts and Sciences. - Lee T. Schalop是Oncoceutics，Inc.的联合创始人，该公司是一家临床阶段药物发现和开发公司，2009年至2021年在Oncoceutics担任过多个行政职务，包括2009年至2016年的首席商务官、2016年至2020年的首席运营官以及2020年至2021年1月的首席执行官，当时Oncoceutuics以4.5亿美元的价格出售给了Chimerix Inc.（NASD：CMRX）。在共同创立Oncoceutics之前，沙洛普博士曾就读于阿尔伯特·爱因斯坦医学院，于2008年获得医学博士学位。在上医学院之前，沙洛普博士曾在几家华尔街大公司的金融行业工作了超过19年，包括摩根士丹利、J.P. Morgan、瑞士信贷和美银证券，其中包括1985年至1993年担任投资银行家，以及1993年至2004年担任研究分析师。Schalop博士在TME Pharma N.V.（Euronext Growth Paris：ALTME）的监事会任职，并曾担任Chimerix公司的董事会观察员，直到该公司于2025年4月出售给爵士制药。他还是宾夕法尼亚大学生命科学与管理Vagelos项目顾问委员会成员。他以优异成绩毕业于宾夕法尼亚大学，在那里他获得了该大学沃顿商学院和文理学院的双学位。
- Lee T. Schalop,has served as a director since July 2025. In 2009, Dr. Schalop was a co-founder of Oncoceutics, Inc., a clinical-stage drug discovery and development company, and served in various executive roles at Oncoceutics from 2009 to 2021, including Chief Business Officer from 2009 to 2016, Chief Operating Officer from 2016 to 2020 and Chief Executive Officer from 2020 to January 2021, at which time Oncoceutuics was sold to Chimerix Inc. (NASD: CMRX) for $450 million. Prior to co-founding Oncoceutics, Dr. Schalop attended the Albert Einstein College of Medicine, graduating with a doctor of medicine degree in 2008. Before attending medical school, Dr. Schalop spent more than 19 years in the financial industry at several major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of America Securities, including serving as an investment banker from 1985 to 1993 and a research analyst from 1993 to 2004. Dr. Schalop serves on the Supervisory Board of TME Pharma N.V. (Euronext Growth Paris: ALTME), and he served as a Board Observer at Chimerix Inc. until its sale to Jazz Pharmaceuticals in April 2025. He also sits on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania. He is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University's Wharton School and College of Arts and Sciences.
高管简历
中英对照 | 中文 | 英文- Panna Sharma
Panna Sharma自2018年7月起担任我们的首席执行官兼总裁，自2018年8月起担任董事。作为首席执行官，Sharma先生监督我们使用AI和基因组学来开发我们的治疗产品线，以创新肿瘤学中精密疗法的拯救，振兴和发展。从2010年5月至2018年2月，Sharma先生担任纳斯达克公司Cancer Genetics的总裁，首席执行官兼董事，该公司为全球医疗机构提供基于DNA的癌症诊断和服务。Sharma先生于2001年创立了TSG Partners，这是一家专业咨询集团，将企业战略和企业融资结合在一起，为生命科学、生物技术和环境科学领域的公司和投资者创造股东价值。在加入TSG之前，Sharma先生曾担任IXL Inc.的电子商务解决方案高级副总裁和首席战略官，该公司后来与Scient合并。在加入IXL Inc.之前的六年里，Sharma先生帮助成功地创立，管理和出售或上市了另外两家咨询和专业服务公司。Sharma从1996年到1998年担任Interactive Solutions，Inc.合伙人。在此之前，Sharma先生曾担任Putnam Investment Management，LLC和美国银行公司的顾问。Sharma先生持有波士顿大学（Boston University）科学哲学、神经网络与人工智能理学学士学位。
Panna Sharma,oversees Lantern Pharma Inc. Lantern Pharma Inc. e of AI and genomics in developing Lantern Pharma Inc. therapy product pipeline to innovate the rescue, revitalization and development of precision therapeutics in oncology. From May 2010 to February 2018, Mr. Sharma served as President, Chief Executive Officer and director of Cancer Genetics, a Nasdaq company and provider of DNA-based cancer diagnostics and services to medical institutions throughout the world. In 2001, Mr. Sharma founded TSG Partners, a specialty advisory group combining corporate strategy and corporate finance to create stockholder value for companies and investors in the life sciences, biotechnology and environmental sciences sectors. Prior to TSG, Mr. Sharma served in the roles of Senior Vice President of E-Business Solutions and Chief Strategy Officer at iXL Inc. (later merged with Scient). For the six years prior to his being at iXL Inc., Mr. Sharma helped successfully found, manage and sell or take public two other consulting and professional services firms. From 1996 to 1998, Mr. Sharma was a partner at Interactive Solutions, Inc. Prior to that, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma currently serves as a Board member of Continental Lithium, Inc. Mr. Sharma holds a Bachelor of Science in the Philosophy of Science, Neural Networks and Artificial Intelligence from Boston University.- Panna Sharma自2018年7月起担任我们的首席执行官兼总裁，自2018年8月起担任董事。作为首席执行官，Sharma先生监督我们使用AI和基因组学来开发我们的治疗产品线，以创新肿瘤学中精密疗法的拯救，振兴和发展。从2010年5月至2018年2月，Sharma先生担任纳斯达克公司Cancer Genetics的总裁，首席执行官兼董事，该公司为全球医疗机构提供基于DNA的癌症诊断和服务。Sharma先生于2001年创立了TSG Partners，这是一家专业咨询集团，将企业战略和企业融资结合在一起，为生命科学、生物技术和环境科学领域的公司和投资者创造股东价值。在加入TSG之前，Sharma先生曾担任IXL Inc.的电子商务解决方案高级副总裁和首席战略官，该公司后来与Scient合并。在加入IXL Inc.之前的六年里，Sharma先生帮助成功地创立，管理和出售或上市了另外两家咨询和专业服务公司。Sharma从1996年到1998年担任Interactive Solutions，Inc.合伙人。在此之前，Sharma先生曾担任Putnam Investment Management，LLC和美国银行公司的顾问。Sharma先生持有波士顿大学（Boston University）科学哲学、神经网络与人工智能理学学士学位。
- Panna Sharma,oversees Lantern Pharma Inc. Lantern Pharma Inc. e of AI and genomics in developing Lantern Pharma Inc. therapy product pipeline to innovate the rescue, revitalization and development of precision therapeutics in oncology. From May 2010 to February 2018, Mr. Sharma served as President, Chief Executive Officer and director of Cancer Genetics, a Nasdaq company and provider of DNA-based cancer diagnostics and services to medical institutions throughout the world. In 2001, Mr. Sharma founded TSG Partners, a specialty advisory group combining corporate strategy and corporate finance to create stockholder value for companies and investors in the life sciences, biotechnology and environmental sciences sectors. Prior to TSG, Mr. Sharma served in the roles of Senior Vice President of E-Business Solutions and Chief Strategy Officer at iXL Inc. (later merged with Scient). For the six years prior to his being at iXL Inc., Mr. Sharma helped successfully found, manage and sell or take public two other consulting and professional services firms. From 1996 to 1998, Mr. Sharma was a partner at Interactive Solutions, Inc. Prior to that, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma currently serves as a Board member of Continental Lithium, Inc. Mr. Sharma holds a Bachelor of Science in the Philosophy of Science, Neural Networks and Artificial Intelligence from Boston University.
- David R. Margrave
DavidR.Margrave自2019年11月起担任我们的首席财务官，自2018年6月起担任我们的秘书。Margrave先生自2016年1月起担任生命科学顾问，为不断发展的生命科学公司提供战略咨询和法律服务。从1995年1月到2015年12月，他曾担任Bionumerick Pharmaceuticals公司（生命科学公司，专注于推进创新癌症疗法）的执行官。在Bionumerick Pharmaceuticals，Inc.任职期间，Margrave先生担任过各种职务，包括and General Counsel担任总裁和首席行政官。Margrave先生自2016年1月起担任Bionumerick Pharmaceuticals，Inc.的顾问。2015年4月至2016年12月，他还担任MedCare Investment Corporation（一家投资于医疗和梦百合服务行业的私人投资公司）的高级法律顾问。在加入Bionumerick Pharmaceuticals，Inc.之前，Margrave先生是Andrews&Kurth LLP（一家国家律师事务所）的合伙人。Margrave先生担任得克萨斯州梦百合和生物科学研究所的主席和董事会成员，并担任得克萨斯州产品开发和小企业孵化器委员会的主席和董事会成员。他是德州技术转让协会（Texas Technology Transfer Association）的前任董事会成员。Margrave先生在斯坦福大学（Stanford University）获得经济学与石油工程文学与理学学士学位，并在德克萨斯大学法学院（University of Texas School of Law）获得法学博士学位。
David R. Margrave,From January 2016 until November 2019, Mr. Margrave served as a life science consultant, providing strategic advisory and legal services to growing life science companies. From January 1995 to December 2015, he served as an executive officer at BioNumerik Pharmaceuticals, Inc., a life science company focused on advancing innovative cancer therapies. During his time at BioNumerik Pharmaceuticals, Inc., Mr. Margrave served in various positions including service as President and as Chief Administrative Officer and General Counsel. Mr. Margrave has served as a consultant to BioNumerik Pharmaceuticals, Inc. since January 2016. From April 2015 to December 2016, he also served as Senior Legal Advisor to MedCare Investment Corporation, a private investment firm investing in the medical and healthcare services industries. Prior to joining BioNumerik Pharmaceuticals, Inc., Mr. Margrave was a partner at Andrews & Kurth LLP, a national law firm. Mr. Margrave serves as Chairman and a board member of the Texas Healthcare and Bioscience Institute and is a past Chairman and board member of the State of Texas Product Development & Small Business Incubator Board. He is a past board member of the Texas Technology Transfer Association. Mr. Margrave received a Bachelor of Arts and Science degree in Economics and in Petroleum Engineering from Stanford University, and a J.D. degree from The University of Texas School of Law.- DavidR.Margrave自2019年11月起担任我们的首席财务官，自2018年6月起担任我们的秘书。Margrave先生自2016年1月起担任生命科学顾问，为不断发展的生命科学公司提供战略咨询和法律服务。从1995年1月到2015年12月，他曾担任Bionumerick Pharmaceuticals公司（生命科学公司，专注于推进创新癌症疗法）的执行官。在Bionumerick Pharmaceuticals，Inc.任职期间，Margrave先生担任过各种职务，包括and General Counsel担任总裁和首席行政官。Margrave先生自2016年1月起担任Bionumerick Pharmaceuticals，Inc.的顾问。2015年4月至2016年12月，他还担任MedCare Investment Corporation（一家投资于医疗和梦百合服务行业的私人投资公司）的高级法律顾问。在加入Bionumerick Pharmaceuticals，Inc.之前，Margrave先生是Andrews&Kurth LLP（一家国家律师事务所）的合伙人。Margrave先生担任得克萨斯州梦百合和生物科学研究所的主席和董事会成员，并担任得克萨斯州产品开发和小企业孵化器委员会的主席和董事会成员。他是德州技术转让协会（Texas Technology Transfer Association）的前任董事会成员。Margrave先生在斯坦福大学（Stanford University）获得经济学与石油工程文学与理学学士学位，并在德克萨斯大学法学院（University of Texas School of Law）获得法学博士学位。
- David R. Margrave,From January 2016 until November 2019, Mr. Margrave served as a life science consultant, providing strategic advisory and legal services to growing life science companies. From January 1995 to December 2015, he served as an executive officer at BioNumerik Pharmaceuticals, Inc., a life science company focused on advancing innovative cancer therapies. During his time at BioNumerik Pharmaceuticals, Inc., Mr. Margrave served in various positions including service as President and as Chief Administrative Officer and General Counsel. Mr. Margrave has served as a consultant to BioNumerik Pharmaceuticals, Inc. since January 2016. From April 2015 to December 2016, he also served as Senior Legal Advisor to MedCare Investment Corporation, a private investment firm investing in the medical and healthcare services industries. Prior to joining BioNumerik Pharmaceuticals, Inc., Mr. Margrave was a partner at Andrews & Kurth LLP, a national law firm. Mr. Margrave serves as Chairman and a board member of the Texas Healthcare and Bioscience Institute and is a past Chairman and board member of the State of Texas Product Development & Small Business Incubator Board. He is a past board member of the Texas Technology Transfer Association. Mr. Margrave received a Bachelor of Arts and Science degree in Economics and in Petroleum Engineering from Stanford University, and a J.D. degree from The University of Texas School of Law.
- Kishor G. Bhatia
KishorG.Bhatia自2019年12月起担任我们的首席科学官，自2019年1月起担任我们的科学顾问。Bhatia博士自2016年12月起还担任我们的合作者之一Reprocell的科学顾问，并于2016年12月至2019年11月担任CancerGenetics，Inc.的科学顾问。2006年以来，他一直担任the National Cancer Institute（癌症流行病学和遗传学部门）的兼职研究员。从2007年1月至2016年7月，Bhatia博士还担任国家癌症研究所艾滋病毒和艾滋病恶性肿瘤办公室艾滋病恶性肿瘤项目主任，从2004年1月到2007年1月，他曾担任the National Cancer Institute（癌症治疗和诊断部门）的项目董事、艾滋病毒和癌症董事。Bhatia博士在浦那大学（University of Pune）获得微生物学理学学士学位，在孟买大学（University of Mumbai）获得生物化学博士学位，是英国皇家病理学学院的院士，并曾是约翰霍普金斯大学（Johns Hopkins University）的博士后以及1985-1989年在Georgetown University担任研究助理教授。
Kishor G. Bhatia,has also served as a scientific consultant to Reprocell, one of Lantern Pharma Inc. collaborators, since December 2016, and served as a scientific consultant to Cancer Genetics, Inc. from December 2016 until November 2019. Since 2006, he has been employed as an Adjunct Investigator with the National Cancer Institute-Division of Cancer Epidemiology and Genetics. From January 2007 until July 2016, Dr. Bhatia also served as a Director-AIDS Malignancy Program at the National Cancer Institute-Office of HIV and AIDS Malignancy, and from January 2004 through January 2007, he served as a Program Director and the Director of HIV and Cancer at the National Cancer Institute-Division of Cancer Treatment and Diagnosis. Dr. Bhatia received a Bachelor of Science degree in microbiology from the University of Pune and a Ph.D. in biochemistry from the University of Mumbai and is a Fellow of the Royal College of Pathology in the United Kingdom and was a Post-Doctoral Fellow at Johns Hopkins University and a Research Assistant Professor at Georgetown University from 1985 to 1989.- KishorG.Bhatia自2019年12月起担任我们的首席科学官，自2019年1月起担任我们的科学顾问。Bhatia博士自2016年12月起还担任我们的合作者之一Reprocell的科学顾问，并于2016年12月至2019年11月担任CancerGenetics，Inc.的科学顾问。2006年以来，他一直担任the National Cancer Institute（癌症流行病学和遗传学部门）的兼职研究员。从2007年1月至2016年7月，Bhatia博士还担任国家癌症研究所艾滋病毒和艾滋病恶性肿瘤办公室艾滋病恶性肿瘤项目主任，从2004年1月到2007年1月，他曾担任the National Cancer Institute（癌症治疗和诊断部门）的项目董事、艾滋病毒和癌症董事。Bhatia博士在浦那大学（University of Pune）获得微生物学理学学士学位，在孟买大学（University of Mumbai）获得生物化学博士学位，是英国皇家病理学学院的院士，并曾是约翰霍普金斯大学（Johns Hopkins University）的博士后以及1985-1989年在Georgetown University担任研究助理教授。
- Kishor G. Bhatia,has also served as a scientific consultant to Reprocell, one of Lantern Pharma Inc. collaborators, since December 2016, and served as a scientific consultant to Cancer Genetics, Inc. from December 2016 until November 2019. Since 2006, he has been employed as an Adjunct Investigator with the National Cancer Institute-Division of Cancer Epidemiology and Genetics. From January 2007 until July 2016, Dr. Bhatia also served as a Director-AIDS Malignancy Program at the National Cancer Institute-Office of HIV and AIDS Malignancy, and from January 2004 through January 2007, he served as a Program Director and the Director of HIV and Cancer at the National Cancer Institute-Division of Cancer Treatment and Diagnosis. Dr. Bhatia received a Bachelor of Science degree in microbiology from the University of Pune and a Ph.D. in biochemistry from the University of Mumbai and is a Fellow of the Royal College of Pathology in the United Kingdom and was a Post-Doctoral Fellow at Johns Hopkins University and a Research Assistant Professor at Georgetown University from 1985 to 1989.